Rajinder Singh

Author:

Rajinder Singh

ISBN #:

0007161492

Author:

Rajinder Singh

ISBN #:

0007161506

Author:

Rajinder Singh

ISBN #:

0918224357

Author:

Rajinder Singh

ISBN #:

0918224527

Author:

Rajinder Singh

ISBN #:

0918224535

Author:

Rajinder Singh

ISBN #:

0918224543

Author:

Rajinder Singh

ISBN #:

0918224594

Author:

Rajinder Singh

ISBN #:

8171160506

Address:

37293 Flin Cmn, Fremont, CA 94536

VIN:

3FAHP0HA9CR365766

Make:

FORD

Model:

FUSION

Year:

2012

US Patent:

6759538, Jul 6, 2004

Filed:

Nov 1, 2002

Appl. No.:

10/286017

Inventors:

Rajinder Singh - Walnut Creek CA
Dane Goff - Redwood CA
Henry Lu - Foster City CA
Thomas Sun - Fremont CA

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61P 4300

US Classification:

548240, 514400, 514406, 5482676, 5483751, 5483381

Abstract:

The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

US Patent:

7060827, Jun 13, 2006

Filed:

Jun 1, 2004

Appl. No.:

10/858343

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 239/02

US Classification:

544323, 544324, 544320

Abstract:

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

US Patent:

7115642, Oct 3, 2006

Filed:

May 3, 2004

Appl. No.:

10/838133

Inventors:

Rajinder Singh - Belmont CA, US
Dane Goff - Redwood City CA, US
John J. Partridge - Chapel Hill NC, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 31/415
C07D 207/02

US Classification:

514378, 5142368, 544137, 546208, 548240

Abstract:

The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

US Patent:

7122542, Oct 17, 2006

Filed:

Jul 30, 2004

Appl. No.:

10/903870

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Hui Li - Millbrae CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - Burligame CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 19/02
A61K 31/535
C07D 268/36

US Classification:

5142305, 544105

Abstract:

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

US Patent:

7153880, Dec 26, 2006

Filed:

Jun 22, 2004

Appl. No.:

10/873914

Inventors:

Rajinder Singh - Belmont CA, US
Dane Goff - Redwood CA, US
Henry Lu - Foster City CA, US
Sarkiz D. Issakani - San Jose CA, US
Thomas Sun - Fremont CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 31/415
A61P 43/00
C07D 207/02

US Classification:

514378, 5142368, 544137, 546208, 548240

Abstract:

The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

US Patent:

7157473, Jan 2, 2007

Filed:

Aug 22, 2003

Appl. No.:

10/646348

Inventors:

Rajinder Singh - Belmont CA, US
Dane Goff - Redwood City CA, US
John Partridge - Chapel Hill NC, US
Henry H. Lu - Foster City CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 213/02
A61K 31/44

US Classification:

514332, 514333, 514340, 514342, 546255, 546256, 5462681, 5462697

Abstract:

The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.

US Patent:

7220745, May 22, 2007

Filed:

May 15, 2003

Appl. No.:

10/440349

Inventors:

Rajinder Singh - Belmont CA, US
Dane Goff - Redwood City CA, US
John Partridge - Chapel Hills NC, US

Assignee:

Rigel Pharmaceuticals - South San Francisco CA

International Classification:

C07D 271/107
C07D 403/10
C07D 413/10
C07D 413/12
C07D 413/14
A61K 31/4245
A61K 31/454
A61K 31/496
A61K 31/5377
A61P 31/12

US Classification:

5142362, 51425403, 514326, 514364, 544138, 544367, 546187, 546209, 548145

Abstract:

The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

US Patent:

7326790, Feb 5, 2008

Filed:

Apr 30, 2004

Appl. No.:

10/836561

Inventors:

Rajinder Singh - Belmont CA, US
Dane Goff - Redwood City CA, US
John J. Partridge - Chapel Hill NC, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 261/02

US Classification:

548240

Abstract:

The present invention relates to substituted diphenylisoxazole compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.